Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.43 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 7/20 | 0.41 |
| ▸ | GLS | O94925 | 6/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10165783 | 0.90 | MMP13 (0.46) | EGLN2ADAMTS4MMP3MMP13 | |
| SCHEMBL10161792 | 0.82 | ADAMTS4 (0.54) | ADAMTS4MMP3MMP13GLSEPHX2 | |
| SCHEMBL10166025 | 0.82 | ADAMTS4 (0.61) | ADAMTS4MMP3MMP13GLSEPHX2 | |
| SCHEMBL13165528 | 0.80 | MMP13 (0.43) | ADAMTS4MMP3MMP13 | |
| SCHEMBL8255707 | 0.80 | MMP13 (0.47) | ADAMTS4MMP3MMP13 | |
| SCHEMBL8255747 | 0.79 | ADAMTS4 (0.51) | ADAMTS4MMP3MMP13GLSEPHX2 | |
| SCHEMBL10161535 | 0.78 | ADAMTS4 (0.46) | ADAMTS4MMP3MMP13GLSROCK2 | |
| SCHEMBL10166003 | 0.77 | MMP13 (0.58) | EGLN2ADAMTS4MMP3MMP13GLS | |
| SCHEMBL13161107 | 0.77 | MMP13 (0.44) | ADAMTS4MMP3MMP13SMN1; SMN2 | |
| SCHEMBL13161063 | 0.76 | EGLN2 (0.43) | EGLN2ADAMTS4MMP3MMP13LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | EGLN2 338/4885ADAMTS4 38/4885MMP3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.